Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic's Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content: <ul> <li><a class="related-article" href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.21957?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)</a></li> </ul>

The Impacts of Severe Maternal Morbidity

Go beyond the latest discoveries with nuanced, in-depth conversations in Healthy Dialogue, a podcast from the JAMA Network. Host and JAMA Senior Editor, Derek C. Angus, MD, MPH, sits down with the world's leading experts to explore the most pressing issues in health and health care.